Adjuvant Ozonetherapy in Advanced Head and Neck Tumors: A Comparative Study

Background

Radiotherapy for advanced head and neck cancers can lose effectiveness against tumours that are poorly oxygenated, since low-oxygen (hypoxic) tissue is known to resist radiation damage. Researchers in Spain investigated whether ozone therapy - given for its established effect of improving blood flow and tissue oxygenation - might work alongside radiotherapy to help counter this hypoxia problem in patients with advanced head and neck tumours.

Study design

This prospective comparative study followed 19 patients with advanced head and neck tumours treated over a three-year period, all receiving a non-standard fractionated course of radiotherapy alongside the oral chemotherapy drug tegafur. Patients were divided into two groups based on the additional treatment they received: 12 patients received intravenous chemotherapy before and/or during radiotherapy, while 7 patients received systemic ozone therapy twice weekly during radiotherapy. This was not a randomised trial - the ozonetherapy group happened to be older on average (64 versus 54 years) and had a much higher rate of lymph node involvement (71% versus 8%) than the chemotherapy group, meaning the two groups started from different levels of disease severity.

Findings

There was no statistically significant difference in overall survival between the two groups: median survival was 6 months in the chemotherapy group and 8 months in the ozonetherapy group. This result occurred despite the ozonetherapy group having worse baseline prognostic factors - older age and more advanced lymph node involvement - which would ordinarily be expected to predict poorer survival.

What the authors concluded

The authors concluded that tumour hypoxia and poor blood flow are known to limit how well radiotherapy and chemotherapy work, and that ozone therapy's ability to improve blood flow and tissue oxygenation may have contributed a positive effect during treatment. They stressed that these findings should be viewed with caution given the very small number of patients involved, and called for further investigation into ozone therapy as an adjuvant to chemoradiotherapy for these tumours.

Limitations of this study

This was a small, non-randomised comparison of only 19 patients split into uneven groups (12 versus 7), which severely limits statistical power and the ability to draw firm conclusions. The two groups were not matched at baseline - the ozonetherapy group was older and had substantially more advanced nodal disease - so the apparent similarity in survival could reflect differences in group composition rather than a true treatment effect. There was no blinding or randomisation, no control group receiving neither adjuvant therapy, and the study was not designed or powered to detect a difference between treatments. This study concerns adjuvant ozone therapy in advanced head and neck tumours. It does not establish ozone as a treatment or cure for cancer itself. Ozone therapy is a complementary approach and should always be discussed with your oncology team.